Biologics in severe asthma: a state-of-the-art review.

Eur Respir Rev · 2025 · PMC11707604 · PMID 39778920

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Tezepelumab reduced airway hyperresponsiveness to mannitol, subepithelial and bronchoalveolar lavage eosinophils, and showed a trend towards reduction in airway tissue mast cells in the UPSTREAM study [ 144 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.